Sorafenib
A drug for liver cancer that could not be treated by surgery. While it extended median survival by about three months in clinical trials, real-world data showed little to no benefit, and it only provided a 50% survival duration compared to the placebo arm in trials.
Save the 2 videos on Sorafenib to your own pod.
Sign up free to keep building your knowledge base on Sorafenib as more episodes are added.
Videos Mentioning Sorafenib
#133 - Vinay Prasad, M.D., M.P.H: Hallmarks of successful cancer policy
Peter Attia MD
A drug for liver cancer that could not be treated by surgery. While it extended median survival by about three months in clinical trials, real-world data showed little to no benefit, and it only provided a 50% survival duration compared to the placebo arm in trials.
409 ‒ Inside modern drug development: the science, economics, and regulatory hurdles
Peter Attia MD
A multikinase inhibitor used to treat renal cell carcinoma and hepatocellular carcinoma, which causes skin cancers as a side effect, illustrating a cancer protective pathway.